RecruitingPhase 2Phase 3NCT07730723

The Effect of Nicorandil on Rheumatoid Arthritis Patients

The Effect of Nicorandil on Disease Activity in Rheumatoid Arthritis Patients


Sponsor

Ain Shams University

Enrollment

70 participants

Start Date

Sep 6, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this clinical trial is to determine whether nicorandil works in minimizing disease severity in patients with rheumatoid arthritis. The study will also assess the safety and tolerability of nicorandil. The main questions it aims to answer are: * Could nicorandil improve disease severity and symptoms of rheumatoid arthritis? * Does nicorandil lower the number of times participants need to use pain relieve medications? * Does the nicorandil improve participants functionality and ability to carry out daily activity? * Does nicorandil correct disease-associated damage and inflammation? * What side effects do participants have when taking nicorandil? Researchers will compare nicorandil to a placebo (a look-alike substance that contains no drug) to see if nicorandil works to decrease symptoms and severity of rheumatoid arthritis. Participants will: * Take nicorandil or a placebo two times daily for 3 months * Visit the clinic once every month for checkups * Keep a diary of their symptoms and the number of times they use a pain reliever


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Nicorandil Oral Tablet, a drug called Placebo, and others for people with rheumatoid arthritis (ra). The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNicorandil Oral Tablet

Nicorandil 10 mg oral tablets will be taken as one tablet twice daily for 3 months (12 weeks).

DRUGPlacebo

Placebo oral tablets will be taken as one tablet twice daily for 3 months (12 weeks).

DRUGconventional synthetic antirheumatic drugs (cDMARDs)

A single or combination of cDMARDs and dose depend on disease severity.


Locations(1)

Ain Shams University Hospitals

Cairo, Abbasia, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07730723


Related Trials